89bio

89bio Share Buybacks

Delisted

The Share Buybacks of 89bio (ETNB) as of Nov 8, 2026 is 356,000.00 USD. In the previous year, Share Buybacks was 268,000.00 USD — a change of 32.84% (higher).

Share Buybacks

356,000.00USD

YoY

32.84%

Last updated:

Share Buybacks of 89bio is 2024 356,000.00 USD. Share Buybacks of 89bio was 2023 268,000.00 USD. It decreases by 32.84% higher compared to the previous year.

The 89bio Share Buybacks history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Share Buybacks
Date
Share Buybacks
Jan 1, 2018
23.67 M USD
Jan 1, 2019
107.70 M USD
Jan 1, 2020
134,000.00 USD
Jan 1, 2021
144,000.00 USD
Jan 1, 2022
-298,000.00 USD
Jan 1, 2023
268,000.00 USD
Jan 1, 2024
356,000.00 USD
The 89bio Share Buybacks history
YEARShare BuybacksYoY
356,000.00USD+32.84%
268,000.00USD-189.93%
-298,000.00USD-306.94%
144,000.00USD+7.46%
134,000.00USD-99.88%
107.70 MUSD+355.11%
23.67 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

89bio Stock analysis

What does 89bio do? 89Bio Inc is an emerging biopharmaceutical company focused on developing drugs to treat metabolic and liver diseases. The company was founded in 2018 and is headquartered in San Francisco, California. 89Bio's business model is based on utilizing innovative science and technology to develop novel and effective therapeutic options for diseases that are currently only limitedly treatable. The company has assembled an interdisciplinary team of scientists, physicians, and entrepreneurs with extensive experience in the pharmaceutical industry. 89Bio has two main divisions: Endocrine and Liver Diseases. In the field of Endocrine Diseases, the company has developed a platform technology based on the binding of human proteins with high affinity and specificity. This technology aims to treat hormone deficiencies in patients with certain endocrine disorders. An example of the application of this technology is 89Bio's leading product, BIO89-100, which is currently in development for the treatment of hypoparathyroidism. The second division of 89Bio is Liver Diseases. The company has developed a pipeline of drug candidates for liver diseases such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These diseases are a growing public health concern worldwide as they are associated with obesity, diabetes, and other metabolic disorders. The leading product in this pipeline is BIO89-1000, which aims to improve liver function by activating a specific group of receptors in the body. In recent years, 89Bio has established strong partnerships with leading companies in the pharmaceutical industry to accelerate its research and development. The company has also received funding from renowned global investors to support its growth and expansion. Overall, 89Bio Inc has a promising future as it focuses on developing therapeutic options for serious diseases that are currently inadequately treated. The company has a strong foundation in research and technology, as well as the experience of its leadership team and partnerships. With its new and innovative approaches, 89Bio can make a sustainable contribution to improving healthcare and patient well-being. 89bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 89bio stock

Share Buybacks of 89bio is 356,000.00 USD in 2024.

Share Buybacks of 89bio changed from 268,000.00 USD to 356,000.00 USD, representing a 32.84% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Share Buybacks 89bio since 2006 – with annual values, charts, and detailed analysis.

Share buybacks represent the cash spent repurchasing the company's own shares. Buybacks reduce shares outstanding and can increase EPS.

Share Buybacks's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Share Buybacks's 89bio historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — 89bio

All Key Metrics — 89bio